XASX
1AD
Market cap1mUSD
Jul 10, Last price
0.00AUD
1D
0.00%
1Q
0.00%
Jan 2017
-97.56%
IPO
-98.46%
Name
Adalta Ltd
Chart & Performance
P/E
—
P/S
3.59
EPS
—
Div Yield, %
—
Shrs. gr., 5y
31.09%
Rev. gr., 5y
-29.28%
Revenues
677k
-61.04%
Net income
-5m
L-16.33%
CFO
-3m
L-44.17%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and other related fibrotic diseases. The company has forged strategic alliances, including a collaboration with GE Healthcare to identify i-bodies that bind to granzyme B, and a partnership with Carina Biotech Pty Ltd. focused on developing CAR-T cell products designed to target various solid tumor antigens. AdAlta Limited was founded in 2006 and is headquartered in Bundoora, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||